What is the current role for HT in postmenopausal women in the prevention and treatment of osteoporosis?
In the wake of publication of the findings of the combination HT arm of the WHI study in July 2002, the FDA changed labeling on conjugated equine estrogen products; these are now approved for treatment of moderate to severe vasomotor symptoms, and for prevention of postmenopausal osteoporosis after consideration of all other options and when risk of osteoporosis outweighs risks of CEE products (1). The FDA asked manufacturers of other estrogen products to adopt similar labeling. The United States Preventive Task Force (USPTF) and other groups recommend against the routine use of combination HT or of unopposed estrogen for the prevention of chronic disease in postmenopausal women (2).
